Exploring WSD0628: A CNS-Penetrable ATM Inhibitor for Radiosensitization in Recurrent Brain Cancer
Time: 2:50 pm
day: Day One
Details:
- Investigating WSD0628's pharmacokinetic properties to determine its brain penetration efficacy and systemic exposure
- Evaluating the synergistic effects of WSD0628 combined with radiation therapy in recurrent brain cancer models, focusing on therapeutic outcomes and safety
- Assessing the impact on survival in preclinical intracranial models, including glioblastoma, DIPG, and brain metastases, to understand potential clinical benefits
